The Pharmacogenefics Research Network (PGRN) has matured to the point that there are now numerous network activities, such that an administrative support structure for the network is needed. Many of the PGRN Logistics Resource functions described herein have been historically handled by the PGRN Program Director (Dr. Rochelle Long), commercial meeting planners, or the PharmGKB. With the increased activities of the PGRN, it is unrealistic and an inefficient use of the Dr. Long's scientific expertise to have her and her office serve the network in so many administrative capacifies. Additionally, the PharmGKB has historically been funded under the PGRN, and one of its functions has been to provide the PGRN with a website. However, the PharmGKB will now be funded under a separate RFA and will no longer be part of the PGRN. As such, a PGRN website is needed. Finally, the PGRN holds twice annual scientific meetings, along with face to face Steering Committee meetings, and organization of these meetings could be more efficiently handled through a central PGRN administrafive site than through the current process of government bidding and contracting of meefing planners. Thus, the network is in crifical need of a network resource that would provide logistics infrastructure to the network and its activities.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01GM074492-09
Application #
8520320
Study Section
Special Emphasis Panel (ZRG1-GGG-M)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
9
Fiscal Year
2013
Total Cost
$1,900,848
Indirect Cost
$274,485
Name
University of Florida
Department
Type
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Chang, S-W; McDonough, C W; Gong, Y et al. (2016) Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. Pharmacogenomics J :
Hamadeh, I S; Shahin, M H; Lima, S M et al. (2016) Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. Clin Transl Sci 9:36-42
Daneshjou, Roxana; Cavallari, Larisa H; Weeke, Peter E et al. (2016) Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Mol Genet Genomic Med 4:513-20
Weng, Liming; Taylor, Kent D; Chen, Yii-Der Ida et al. (2016) Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiol Genomics 48:12-20
Gharaibeh, Kamel A; Turner, Stephen T; Hamadah, Abdurrahman M et al. (2016) Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. Am J Hypertens 29:1186-94
Johnson, J A; Weitzel, K W (2016) Advancing Pharmacogenomics as a Component of Precision Medicine: How, Where, and Who? Clin Pharmacol Ther 99:154-6
Shahin, Mohamed H; Gong, Yan; McDonough, Caitrin W et al. (2016) A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension 68:621-9
Shahin, Mohamed H; Johnson, Julie A (2016) Mechanisms and pharmacogenetic signals underlying thiazide diuretics blood pressure response. Curr Opin Pharmacol 27:31-7
Hoh, Brian L; Gong, Yan; McDonough, Caitrin W et al. (2016) CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg 124:1746-51
Solayman, Mohamed Hassan M; Langaee, Taimour; Patel, Archanakumari et al. (2016) Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Mol Biotechnol 58:179-87

Showing the most recent 10 out of 152 publications